Dr Ameera Patel, CEO of TidalSense, explains how AI could completely change diagnostics in respiratory care.

Respiratory diseases affect one in five people. Already the third biggest cause of death in the UK, the number of people impacted by these conditions is rising. The latest NHS figures show that hospital admissions for respiratory illnesses are very close to pre-pandemic levels. Furthermore, analysis by Asthma and Lung UK also highlights a direct link between admissions and deprivation, due to factors like increased exposure to air pollution, dampness and mould.

Against a backdrop of NHS pressures – most notably, rising numbers of patients with long-term health conditions, and widespread staff shortages – diagnosis of respiratory diseases is not keeping pace with the growing prevalence of respiratory conditions.

If we take chronic obstructive pulmonary disease (COPD) as an example, around two thirds of people with the disease in the UK are undiagnosed, with one third only identified once they are admitted to hospital, when it is likely their disease is already significantly advanced and their symptoms severe. This goes a long way to explaining why the UK has the second highest death rate from lung disease in Europe, second only to Turkey.

For lung conditions, starting treatment early is critical. For asthma and COPD effective treatment reduces symptoms and exacerbations, reducing healthcare visits – including emergency hospital admissions. But the current clinical pathway for respiratory conditions is ineffective, inefficient and expensive – many patients are misdiagnosed and aren’t escalated into appropriate treatment quickly enough. COPD alone is the second most common reason for an emergency hospital admission and total admissions for COPD are estimated to cost the NHS £491 million annually.

This contributes significantly to the NHS’ financial burden – all lung conditions (including lung cancer) cost the health service around £11 billion annually. COPD and asthma, the two biggest chronic respiratory conditions which affect one in five people in England, cost the NHS around £5 billion each year.

Doing away with misdiagnosis

Early and accurate diagnosis is critical to easing the mounting pressure on our health service, eliminating unnecessary patient appointments while enabling earlier interventions for those who urgently need them.

But current diagnostic methods present a significant barrier to this goal. For example, the current test for COPD and asthma is spirometry, an early-Victorian technology that can be unpleasant for patients and requires specialist training to operate. Not only is this 180-year-old approach complex to perform, but it is also dependent on patient technique. What’s more, abnormal results can be challenging to interpret, meaning that misdiagnosis is rife.

Access to spirometry tests is patchy at best and diagnostic testing completely shut down during the pandemic. Conservative estimates predict there are around 27,000-34,000 people currently awaiting a diagnostic test.

Integrating new technologies – such as AI – is needed to get to grips with the backlog, and open the possibility of accurate, fast diagnoses.

It’s perhaps not surprising, therefore, that The NHS Long Term Plan prioritises accurate early diagnosis and access to testing for chronic respiratory diseases as a way to create efficiencies for the NHS, and improve the quality of treatment and care for patients.

More than the human eye can see

Thanks to its ability to analyse and understand large quantities of clinical information, AI has huge potential to pave the way to highly accurate diagnoses. AI-led technology is already being applied to the assessment of everything from stroke detection through to retinal screening, using trained algorithms and deep learning to quickly detect signs of disease that may not have been visible to clinicians.

There have already been successful demonstrations of identifying respiratory conditions using existing clinical data. For example, AI has been applied to aid the diagnosis of lung cancer and pulmonary fibrosis to help clinicians identify at-risk patients, speed up decision-making and reduce unnecessary procedures.

If applied to respiratory diagnostics, AI could mean that patients with chronic respiratory diseases would be spared the ordeal of spending weeks or months moving between clinicians to secure a diagnosis, instead giving them access to the right treatment, medication, and dosage at the right time. Better disease management could also deliver significant savings to the NHS.

Going beyond diagnostics

AI-led technologies are also opening powerful predictive and forecasting capabilities. For example, these technologies could be used to predict a patient’s future disease development, helping guide clinical decision making and opening access to early medical or lifestyle interventions. AI can even be used to predict the people within populations who are most at risk of developing chronic respiratory disease, ensuring they are prioritised for diagnosis or screening programmes.

At the same time, AI has considerable potential for improving the patient experience – empowering patients to self-monitor and manage their condition outside of the healthcare environment, resulting in a better quality of life for the patient, and further efficiencies for the health service.

In Greater Glasgow and Clyde, 500 COPD patients are being monitored at home to enable earlier interventions while also relieving pressure on the NHS. The scheme combines patient records with real-time data from fitness trackers and at-home breathing equipment, and users can directly message doctors with any health concerns via a smartphone app. A new trial later this year will also apply AI to this data, immediately flagging up patients who might be experiencing more severe symptoms. Early results are positive, suggesting that the scheme has already reduced hospital admissions by over half.

Saving time, saving lives

As the number of patients with chronic respiratory conditions continues to grow, it will be impossible for the NHS to meet its objectives to improve the quality of life and health outcomes of people with respiratory disease, unless the hurdle of diagnosis is overcome first.

Technology will be critical in bridging the gap between patient demand and clinical supply, with AI enabling faster, more accurate diagnoses and opening access to diagnosis outside of the traditional clinical setting. The increased capabilities of digital technologies are paving the way for more effective treatment plans, reducing the likelihood of frequent hospitalisations, and generally contributing to a better quality of life. 



Source link

Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market

Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market

Newark, New Castle, USA - new report, titled Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Obstructive Pulmonary Disease (COPD) Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Obstructive Pulmonary Disease (COPD) Therapeutics market. The report offers an overview of the market, which briefly describes the market condition and the leading segments. It also mentions the top players present in the global Chronic Obstructive Pulmonary Disease (COPD) Therapeutics market.

Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market: www.growthplusreports.com/report/chronic-obstructive-pulmonary-disease-copd-therapeutics-market/8912

Global Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market: Segmentation

For a point by point assessment, the global Chronic Obstructive Pulmonary Disease (COPD) Therapeutics market is divided basis of technology, product, and services. This division of the market permits a detailed scrutiny of the large number of components affecting the market. Analysts have fastidiously examined the changing example of innovation, upcoming trends, ventures made by players in innovative work, and growing number of applications. Moreover, experts have evaluated the changing socioeconomics and changing utilization designs, which are impact the global Chronic Obstructive Pulmonary Disease (COPD) Therapeutics market.

Get a PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, and Chart) : www.growthplusreports.com/inquiry/request-sample/chronic-obstructive-pulmonary-disease-copd-therapeutics-market/8912

SEGMENTATION

GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) THERAPEUTICS MARKET - ANALYSIS & FORECAST, BY DRUG CLASS
Bronchodilators
Short-Acting Bronchodilators
Long-Acting Bronchodilators
Anti-inflammatory Drugs
Oral and Inhaled Steroids
Phosphodiesterase-4 Inhibitors
Others
Antibiotics & Antiviral
Others
GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) THERAPEUTICS MARKET - ANALYSIS & FORECAST, BY THERAPY TYPE
Monotherapy
Combination Therapy
GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) THERAPEUTICS MARKET - ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market Competitive Landscape

The last chapter of the research report on the global Chronic Obstructive Pulmonary Disease (COPD) Therapeutics market focuses on the key players and the competitive landscape present in the market. The report includes a list of strategic initiatives taken by the companies in recent years along with the ones that are expected to happen in the foreseeable future. Researchers have made a note of the financial outlook of these companies, their research and development activities, and their expansion plans for the near future. The research report on the global Chronic Obstructive Pulmonary Disease (COPD) Therapeutics market is a sincere attempt at giving the readers a comprehensive view of the market to interested readers.

Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market Leading Players:

GSK Plc
Boehringer Ingelheim International GmbH
Sunovion Pharmaceuticals Inc.
AstraZeneca Plc
Sanofi S.A.
Viatris Inc.
Novartis AG
Chiesi Farmaceutici S.p.A.
Hanmi Pharmaceutical Company Limited
Inmunotek S.L.

Growth Plus Reports studies the key trends in each category and sub-segment of the Chronic Obstructive Pulmonary Disease (COPD) Therapeutics market, along with global and regional projections from 2023 to 2031. Our research splits the market into product type and application segments.

For More Information or Query or Customization visit: www.growthplusreports.com/inquiry/customization/chronic-obstructive-pulmonary-disease-copd-therapeutics-market/8912

This report is useful in addressing various essential issues for market participants, while also supporting them in making investments and leveraging the market opportunities.

Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market TOC: www.growthplusreports.com/report/toc/chronic-obstructive-pulmonary-disease-copd-therapeutics-market/8912

Market segment by Region/Country including: -

-North America (United States, Canada and Mexico)
-Europe (Germany, UK, France, Italy, Russia and Spain etc.)
-Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.)
-South America (Brazil, Argentina and Colombia etc.)
-Middle East and Africa (South Africa, UAE and Saudi Arabia etc.)

Reasons to Buy This Report

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chronic Obstructive Pulmonary Disease (COPD) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

This report will help stakeholders to understand the global industry status and trends of Chronic Obstructive Pulmonary Disease (COPD) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

This report stays updated with novel technology integration, features, and the latest developments in the market

This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Chronic Obstructive Pulmonary Disease (COPD) Therapeutics industry.

This report helps stakeholders to gain insights into which regions to target globally

This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chronic Obstructive Pulmonary Disease (COPD) Therapeutics .

This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

QUICK BUY: www.growthplusreports.com/checkout-8912

Browse Latest Healthcare Reports:

Pheochromocytoma Market - www.growthplusreports.com/report/pheochromocytoma-market/8764

Electromechanical Operating Table Market - www.growthplusreports.com/report/electromechanical-operating-table-market/8765

High Flow Oxygen Therapy Devices Market - www.growthplusreports.com/report/high-flow-oxygen-therapy-devices-market/8766

Fluoropolymers in Healthcare Market - www.growthplusreports.com/report/fluoropolymers-in-healthcare-market/8767

Vaptans Market - www.growthplusreports.com/report/vaptans-market/8768

Biological APIs Market - www.growthplusreports.com/report/biological-apis-market/8769

Vaginal Speculum Market - www.growthplusreports.com/report/vaginal-speculum-market/8770

Ampicillin Market - www.growthplusreports.com/report/ampicillin-market/8771

Manan Sethi
Director, Market Insights
Email: [email protected]
256 Chapman Road
STE 105-4, Newark,
New Castle - 19702, USA
Phone no: +1 888 550 5009
Web: www.growthplusreports.com/

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020."

This release was published on openPR.

Source link

“Coherent Market Insights offers a 25% discount on Respiratory Devices Market Reports on Single User Access and Unlimited User Access”

What are New Additions in 2023?

1. Detailed industry forecast
2. More information on the company’s key players
3. On-demand customized reports and analyst assistance
4. Recent market developments and future growth prospects
5. Requested customized regional/country reports

Respiratory Devices Market Projections : The global respiratory devices market is estimated to be valued at US$ 21,725.0 million in 2022 and is expected to exhibit a CAGR of 9.1% during the forecast period (2023-2030).

Coherent Market Insights has announced the addition of Respiratory Devices Market 2023 Forecast Analysis by Types, Applications, Size, Share, Key Players, and Regions. a new research report to its market research archive. The Respiratory Devices Market has been thoroughly researched and analysed by industry experts and researchers. The industry is examined at the global, regional, and national levels. The report highlights the primary revenue stream for the estimated year, along with sales volumes, growth patterns, and major industry market dynamics. The historical data is provided, as well as a comprehensive revenue analysis for the forecast period. The report focuses on the size, share, growth status, and future trends of the Respiratory Devices Market, as well as recent business developments.

Medical equipment called a respiratory device is used to help a patient with breathing difficulties. The management and treatment of conditions like fibrosis, asthma, chronic obstructive pulmonary disease (COPD), and acute respiratory distress syndrome (ARDS) make use of these devices. These cutting-edge medical devices, such as oxygen concentrators, nebulizers, ventilators, etc., are beneficial for treating a wide range of disorders. The respiratory device enhances pulmonary functioning and helps clear mucus from the airways.

Ask Us to Get Your Sample Copy Of The Report, Covering TOC and Regional Analysis @ www.coherentmarketinsights.com/insight/request-sample/1299

Note – Updated Version 2023 is available

(The sample of this report is readily available on request. The report sample contains a brief introduction to the research report, a Table of Contents, a Graphical introduction of regional analysis, Top players in the market with their revenue analysis, and our research methodology.)

Report Drivers & Trends Analysis

The report also discusses the factors driving and restraining market growth, as well as their specific impact on demand over the forecast period. Also highlighted in this report are growth factors, developments, trends, challenges, limitations, and growth opportunities. This section highlights emerging Respiratory Devices Market trends and changing dynamics. Furthermore, the study provides a forward-looking perspective on various factors that are expected to boost the market’s overall growth.

Major Key Contents Covered in Market:

  • Market introduction, including market development and status.
  • Analysis and trends in manufacturing technology.
  • Market analysis, including company and country status and competition.
  • According to market estimates, the following business segments are essential.
  • Future growth rate estimation, as well as valuation of each region.
  • A geographical analysis of the product/service consumption in each region.
  • Forecast market analysis by segment.

Major Key Players: Masimo, Teleflex Incorporated, Fisher & Paykel Healthcare Limited, ResMed, Hamilton Medical, Medtronic, Koninklijke Philips N.V., ICU Medical, Inc., General Electric Company, Dragerwerk AG & Co. KGaA, Inogen, Inc., TytoCare Ltd., Belluscura, Mitocon Biomed, VYAIRE, Medline Industries, Inc., OMRON Corporation, TNI medical AG, and Xplore Health Technologies Pvt. Ltd.

???????????????????????????????? ???????????????? ???????????????????????????? ???????????????????????? ???????????????? ???????? ???????? ????????% ???????????? @ www.coherentmarketinsights.com/insight/buy-now/1299

Prominent Industry Insights

The report evaluates the most recent technological advances in the Respiratory Devices Market industry. The research employs a variety of methodologies and analysis tools to ensure accurate and comprehensive market information. For example, it provides in-depth insights into SWOT and PESTLE analysis based on industry segmentations and regional developments. The report provides in-depth segmentation by type, application, and region. Throughout the forecast period, each segment study is provided along with information about production and manufacturing. The analysis of these segments will help to understand the significance of the various market growth factors.

Competitive Landscape Analysis

In any market research analysis, the main field is competition. This section of the report provides a competitive scenario and portfolio of the Respiratory Devices Market’s key players. Major and emerging market players are closely examined in terms of market share, gross margin, product portfolio, production, revenue, sales growth, and other significant factors. Furthermore, this information will assist players in studying critical strategies employed by market leaders in order to plan counterstrategies to gain a competitive advantage in the market.

Furthermore, the report includes a geographical analysis of the market, which serves as a useful tool for participants to investigate sales and business expansion opportunities in various regions and countries. Each regional and country-specific market is thoroughly researched in the geographic overview based on Respiratory Devices Market share, CAGR, size, future growth potential, and other key parameters.

For Additional List and Detail Information on Key Players, Send Your Request for Custom [email protected] www.coherentmarketinsights.com/insight/request-customization/1299

The Regions Covered in This Report Are

  • North America (United States, Canada, and Mexico)
  • Europe (Germany, France, United Kingdom, Russia, Italy, and the Rest of Europe)
  • Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
  • South America (Brazil, Argentina, Colombia, and the rest of South America)
  • The Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, South Africa, and the Rest of the Middle East and Africa)

One of the primary goals of this report is to investigate competitive developments such as partnerships and collaborations, R&D activities, mergers and acquisitions (M&A), product developments, and market expansions. Furthermore, the study provides business predictions by region, key countries, and information on top firms to help them channel their investments. Furthermore, market prospects are provided based on global sales and revenue forecasts as well as regional Respiratory Devices Market forecasts.

Table of Contents with Major Points:

Executive Summary

• Introduction
• Key Findings
• Recommendations
• Definitions and Assumptions

Executive Summary

Market Overview

• Definition of Respiratory Devices Market
• Market Dynamics
• Drivers
• Restraints
• Opportunities
• Trends and Developments

Key Insights

• Key Emerging Trends
• Key Developments Mergers and Acquisition
• New Product Launches and Collaboration
• Partnership and Joint Venture
• Latest Technological Advancements
• Insights on Regulatory Scenario
• Porters Five Forces Analysis

Qualitative Insights Impact of COVID-19 on Global Respiratory Devices Market

• Supply Chain Challenges
• Steps taken by Government/Companies to overcome this impact
• Potential opportunities due to COVID-19 outbreak

Conclusion 

Appendix

• Data Sources
• Abbreviations
• Disclaimer

TOC Continued…!

Some of The Key Questions Answered in This Report

  • What will the market growth rate or momentum be over the forecast period?
  • What was the value of the expanding market?
  • Who are the major players in the industry?
  • What is the anticipated size of the emerging market?
  • Which region is expected to have the largest share of the industry?
  • What are the new opportunities that will allow the industry to grow in the coming years?
  • What are their winning strategies for remaining competitive?

???????????????????????????????? ???????????????? ???????????????????????????? ???????????????????????? ???????????????? ???????? ???????? ????????% ???????????? @ www.coherentmarketinsights.com/insight/buy-now/1299

Read Our More Reports:

Homecare self monitoring device market

Muscle stimulation devices market

Radial compression devices market

Medical devices reimbursement market

 About us:

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Contact:

Mr Shah

Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400,
Burlingame, CA 94010, United States.
Email: [email protected]
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

Source link

NEW YORK - Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO (Respiratory Syncytial Virus Vaccine), the company's bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older.

ABRYSVO is unadjuvanted and composed of two preF proteins selected to optimize protection against RSV A and B strains and was observed to be safe and effective.

'A vaccine to help prevent RSV had been an elusive public health goal for more than half a century. Today's approval is a monumental step forward in delivering on Pfizer's commitment to help alleviate the significant burden of RSV in higher-risk populations, which includes older adults,' said Annaliesa Anderson, Ph.D., Senior Vice President and Chief Scientific Officer, Vaccine Research and Development, Pfizer. 'ABRYSVO will address a need to help protect older adults against the potentially serious consequences of RSV disease. We are extremely grateful to the clinical trial participants, study investigator teams and our dedicated Pfizer colleagues for their roles in making this vaccine available.'

The FDA's decision is based on the data from the pivotal Phase 3 clinical trial (NCT05035212) RENOIR (RSV vaccine Efficacy study iNOlder adults Immunized against RSV disease). RENOIR is a global, randomized, double-blind, placebo-controlled study designed to assess the efficacy, immunogenicity, and safety of a single dose of the vaccinein adults 60 years of age and older. RENOIR has enrolled approximately 37,000 participants, randomized to receive RSVpreF 120 g or placebo in a 1:1 ratio. The results were recently published in The New England Journal of Medicine. RENOIR is ongoing, with efficacy data being collected in the second RSV season in the study.

'This past RSV season demonstrated the serious consequences and potential health risks this virus poses for older adults,' said Edward E. Walsh, MD, Professor of Medicine, University of Rochester Medical Center, and principal RENOIR investigator. 'Today's FDA approval of ABRYSVO recognizes significant scientific progress, and importantly helps provide older adults potential protection against RSV and an opportunity to improve community health by helping prevent the disease.'

RSV is a contagious virus and a common cause of respiratory illness worldwide.2 The virus can affect the lungs and breathing passages of an infected individual, potentially causing severe illness or death.3,4,5 In the U.S., the burden RSV causes in older adults is considerable. The severity of RSV disease can increase with age and comorbidities, such as chronic obstructive pulmonary disease, asthma, and congestive heart failure.6

The U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) will meet on June 21, 2023, to discuss recommendations for the appropriate use of RSV vaccines in older adults. Pending the outcome of this meeting, Pfizer anticipates supply availability in Q3 2023 ahead of the anticipated RSV season this fall.

Earlier this month, Pfizer reported positive top-line results from the Phase 3 study evaluating the safety and immunogenicity of ABRYSVO coadministered with seasonal inactivated influenza vaccine (SIIV) in adults 65 years and older.7 Pfizer intends to publish these results in a peer-reviewed scientific journal. Earlier this month, Pfizer also announced it would be initiating multiple clinical trials evaluating RSVpreF in healthy children ages 2-5; children ages 5-18 with underlying medical conditions; adults ages 18-60 at high-risk due to underlying medical conditions and adults ages 18 and older who are immunocompromised and at high-risk for RSV.8

About ABRYSVO Regulatory Review

On March 24, 2022, Pfizer announced the FDA granted Breakthrough Therapy Designation for ABRYSVO for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older. This decision was followed by the FDA's acceptance of ABRYSVO's Biologics License Application (BLA) under priority review for older adults in November 2022.

Pfizer is currently the only company pursuing regulatory applications for an RSV investigational vaccine candidate for both an indication to help protect older adults, as well as an indication to help protect infants through maternal immunization. Previously, Pfizer announced that the FDA had granted priority review for a BLA for RSVpreF for the prevention of lower respiratory tract and severe lower respiratory tract disease caused by RSV in infants from birth up to six months of age by active immunization of pregnant individuals. Earlier this month, Pfizer announced that the FDA's Vaccines and Related Biological Products Advisory Committee voted that available data support the efficacy and safety of RSVpreF for the maternal indication. The FDA has set a Prescription Drug User Fee Act (PDUFA) action date in August 2023.

In February 2023, it was announced that the European Medicines Agency (EMA) accepted for review Pfizer's Marketing Authorization Application (MAA) under accelerated assessment for RSVpreF, as submitted for both older adults and maternal immunization to help protect infants against RSV. The formal review process by the EMA's Committee for Medicinal Products for Human Use (CHMP) currently is ongoing. Also in February 2023, Pfizer Japan announced an application was filed with the Ministry of Health, Labor and Welfare for RSVpreF as a maternal immunization to help protect infants against RSV. In April 2023, Pfizer Canada announced Health Canada accepted RSVpreF for review for both individuals ages 60 and older and as a maternal immunization to help protect infants against RSV.

About Pfizer: Breakthroughs That Change Patients' Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com.

DISCLOSURE NOTICE

The information contained in this release is as of May 31, 2023. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about ABRYSVO (RSVpreF), including its potential benefits, an approval in the U.S. for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older, an application pending in the U.S. for RSVpreF for the prevention of lower respiratory tract and severe lower respiratory tract disease caused by RSV in infants from birth up to six months of age by active immunization of pregnant individuals, applications pending for RSVpreF in other jurisdictions and plans to initiate clinical trials in other populations, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, uncertainties regarding the commercial success of ABRYSVO (RSVpreF); the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; risks associated with interim data, including the risk that final results from the Phase 3 trials could differ from the interim data;the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when biologic license applications may be filed in particular jurisdictions for ABRYSVO (RSVpreF) for any potential indications; whether and when any applications that may be pending or filed for ABRYSVO (RSVpreF) may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether ABRYSVO (RSVpreF) for any such indications will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of ABRYSVO (RSVpreF); uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities regarding ABRYSVO (RSVpreF) and uncertainties regarding the commercial impact of any such recommendations; uncertainties regarding the impact of COVID-19 on our business, operations and financial results and competitive developments.

Contact:

Email: [email protected]

Tel: +1 (212) 733-1226

Source link

Asthma & COPD Drugs Market - Breathe Freely, Live Fully:

Newark, New Castle, USA - new report, titled Asthma & COPD Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Asthma & COPD Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Asthma & COPD Drugs market. The report offers an overview of the market, which briefly describes the market condition and the leading segments. It also mentions the top players present in the global Asthma & COPD Drugs market.

Asthma & COPD Drugs Market: www.growthplusreports.com/report/asthma-copd-drugs-market/7909

Global Asthma & COPD Drugs Market: Segmentation

For a point by point assessment, the global Asthma & COPD Drugs market is divided basis of technology, product, and services. This division of the market permits a detailed scrutiny of the large number of components affecting the market. Analysts have fastidiously examined the changing example of innovation, upcoming trends, ventures made by players in innovative work, and growing number of applications. Moreover, experts have evaluated the changing socioeconomics and changing utilization designs, which are impact the global Asthma & COPD Drugs market.

Get a PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, and Chart) : www.growthplusreports.com/inquiry/request-sample/asthma-copd-drugs-market/7909

SEGMENTATION

GLOBAL ASTHMA AND COPD DRUGS MARKET - ANALYSIS & FORECAST, BY DISEASE TYPE
Asthma
Chronic Obstructive Pulmonary Diseases (COPD)

GLOBAL ASTHMA AND COPD DRUGS MARKET - ANALYSIS & FORECAST, BY DRUG CLASS
Bronchodilators
Short-Acting Beta-2 Agonists
Long-Acting Beta-2 Agonists
Anticholinergic Agents
Anti-Inflammatory Drugs
Oral And Inhaled Corticosteroids
Anti-Leukotrienes
Phosphodiesterase Disease Type-4 Inhibitors
Monoclonal Antibodies
Combination Drugs

GLOBAL ASTHMA AND COPD DRUGS MARKET - ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Asthma & COPD Drugs Market Competitive Landscape

The last chapter of the research report on the global Asthma & COPD Drugs market focuses on the key players and the competitive landscape present in the market. The report includes a list of strategic initiatives taken by the companies in recent years along with the ones that are expected to happen in the foreseeable future. Researchers have made a note of the financial outlook of these companies, their research and development activities, and their expansion plans for the near future. The research report on the global Asthma & COPD Drugs market is a sincere attempt at giving the readers a comprehensive view of the market to interested readers.

Asthma & COPD Drugs Market Leading Players:

GlaxoSmithKline PLC
Amgen, Inc.
Abbott Laboratories
Merck & Co. Inc.
AstraZeneca PLC
Boehringer Ingelheim GmbH
Novartis AG
Hoffmann-La Roche Ltd
Sanofi S.A.
Teva Pharmaceuticals Industries Ltd.
Vectura Group Plc.
Dr Reddy's Laboratories
Cipla Limited
Mylan N.V.
Glenmark Pharmaceuticals Limited
Aurobindo Pharma Limited

Growth Plus Reports studies the key trends in each category and sub-segment of the Asthma & COPD Drugs market, along with global and regional projections from 2022 to 2030. Our research splits the market into product type and application segments.

For More Information or Query or Customization visit: www.growthplusreports.com/inquiry/customization/asthma-&-copd-drugs-market/7909

This report is useful in addressing various essential issues for market participants, while also supporting them in making investments and leveraging the market opportunities.

Asthma & COPD Drugs Market TOC: www.growthplusreports.com/report/toc/asthma-copd-drugs-market/7909

Market segment by Region/Country including: -

-North America (United States, Canada and Mexico)
-Europe (Germany, UK, France, Italy, Russia and Spain etc.)
-Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.)
-South America (Brazil, Argentina and Colombia etc.)
-Middle East and Africa (South Africa, UAE and Saudi Arabia etc.)

Reasons to Buy This Report

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Asthma & COPD Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

This report will help stakeholders to understand the global industry status and trends of Asthma & COPD Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

This report stays updated with novel technology integration, features, and the latest developments in the market

This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Asthma & COPD Drugs industry.

This report helps stakeholders to gain insights into which regions to target globally

This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Asthma & COPD Drugs .

This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

QUICK BUY: www.growthplusreports.com/checkout-7909

Browse Latest Healthcare Reports:

Gluten Intolerance Treatment Market: www.growthplusreports.com/report/gluten-intolerance-treatment-market/8976

Rapid Antigen Testing Market: www.growthplusreports.com/report/rapid-antigen-testing-market/8977

Actinomycosis Market: www.growthplusreports.com/report/actinomycosis-market/8978

Brain Cancer Diagnostics Market: www.growthplusreports.com/report/brain-cancer-diagnostics-market/8979

Sandhoff Disease Therapeutics Market: www.growthplusreports.com/report/sandhoff-disease-therapeutics-market/8980

Magnetic Beads Market: www.growthplusreports.com/report/magnetic-beads-market/8981

WHIM Syndrome Market: www.growthplusreports.com/report/whim-syndrome-market/8982

Manan Sethi
Director, Market Insights
Email: [email protected]
Phone no: +1 888 550 5009
Web: www.growthplusreports.com/

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020."

This release was published on openPR.

Source link

SciCheck Digest

Ventilators can be lifesaving for critically ill COVID-19 patients. A social media claim that a new study shows ventilators killed “nearly all” COVID-19 patients is “quite wrong,” according to the study’s co-author. Ventilator-associated complications can contribute to deaths, but patients are typically put on ventilators when they would otherwise die.


Full Story

COVID-19 can cause lung damage and respiratory failure. In patients who are unable to breathe well enough to supply oxygen to their bodies, mechanical ventilators can be lifesaving and give them time to recover. Ventilators help people breathe by pushing air into their lungs via a tube inserted down their windpipe.

Yet, social media posts have shared an article from the People’s Voice with a false headline: “Official Report: Ventilators Killed Nearly ALL COVID Patients.” The People’s Voice, formerly News Punch, frequently publishes articles with false and inflammatory headlines.

The posts misrepresent the conclusions of a study published in April in the Journal of Clinical Investigation. The idea that ventilators — and not COVID-19 — killed nearly all COVID-19 patients is “quite wrong,” study co-author Dr. Benjamin Singer, a pulmonary and critical care physician at Northwestern Medicine, told us.

Rep. Thomas Massie, a Republican from Kentucky, also misrepresented the conclusions of the study, tweeting, “How many COVID patients died due to the use of ventilators? A recent examination of the data suggests quite a few.”

The idea that ventilators are dangerous, and not COVID-19, is a misinterpretation of his data, Singer said. “It’s not the ventilator that was the cause of death,” he said. “The ventilator was very much life support for these patients. It was ultimately COVID-19” that caused the deaths.

Singer’s study looked at 585 people put on ventilators due to respiratory failure between 2018 and 2022 at Northwestern Memorial Hospital. These people primarily had COVID-19 or some other infectious disease, such as another viral or bacterial illness.

Around half of these very sick patients who required mechanical ventilation — people who likely would have died without the intervention — went on to survive their illness. The survival rate was similar whether they had COVID-19 or another disease and was consistent with the survival rate for COVID-19 patients on ventilators found in another, larger study.

Singer’s study explored the degree to which a known ventilator-related complication called ventilator-associated pneumonia contributes to death, finding that the complication is more common in people with COVID-19 and, when unresolved, is linked to death. VAP is usually treated with antibiotics.

People with COVID-19 likely have an elevated risk of VAP because they stay on ventilators for longer-than-average periods. COVID-19 also affects the immune system and damages the surface of the lungs in unique ways, Singer said, which could potentially make the lungs more susceptible to secondary infections.

VAP contributes to death in some COVID-19 and other infectious disease patients, explained Dr. Mark Metersky, a pulmonary and critical care physician and professor at the University of Connecticut School of Medicine who was not involved in the study.

However, virtually all of these patients would have died if they had not been put on a ventilator, he said. “It’s not that the ventilator killed them, the ones who died. It’s that the ventilator failed to save them.”

A related claim in a popular post — that medical professionals put patients on ventilators due to financial incentives — is also unsupported by evidence, as we and other fact-checkers previously explained. It’s standard for hospitals to get more money for patients, such as those on ventilators, who require more care.

Study Explored Ventilator-Related Pneumonia

VAP typically occurs as a form of secondary pneumonia, which means it shows up in patients who already have another pneumonia diagnosis, such as pneumonia resulting from COVID-19, the flu or a bacterial infection.

People are diagnosed with pneumonia when their lungs become swollen with fluid from a respiratory infection. VAP typically arises from bacteria introduced to the lungs via the patient’s breathing tube.

Singer’s new paper finds that once very sick COVID-19 patients are on ventilators, they are at greater risk of VAP compared with other similarly ill pneumonia patients, he said.

Further, the paper found that “whether that ventilator-associated pneumonia was cured or not was a major determinant of whether patients went on to live or die in the ICU,” he said. However, just being diagnosed with VAP was not associated with a higher risk of death.

Based on these conclusions, the People’s Voice article makes a false claim, which was shared widely: “Nearly all COVID-19 patients who died in hospital during the early phase of the pandemic were killed as a direct result of being put on a ventilator, a disturbing new report has concluded.”

First, many hospitalized COVID-19 patients have died who never went on ventilators. And Singer’s study was not limited to “the early phase of the pandemic” but rather went through March 2022.

As we’ve said, this line of thinking is also misleading because it does not make it clear that the patients on ventilators would have typically died without them. It is also untrue that Singer’s study showed that ventilator-related complications killed “nearly all” ventilated patients who died.

The People’s Voice article explains its reasoning by saying that “most patients” put on ventilators because of COVID-19 developed VAP. “So while COVID-19 may have put these patients in the hospital, it was actually a secondary infection brought on by the use of a mechanical ventilator that caused their deaths,” the article says.

In reality, 57% of COVID-19 patients on ventilators in the study developed VAP and a quarter of other ventilated pneumonia patients did. Around half of all patients with VAP died, which was “not significantly different” from the death rate in patients on ventilators who didn’t have VAP, according to the study.

Singer and his colleagues did find that patients whose VAP was not successfully treated were more likely to die than patients whose VAP resolved, indicating a connection between VAP and poor outcomes. The study was not randomized, and the researchers write that they cannot definitively determine that unresolved VAP — and not some other factor associated with it — leads to poor outcomes.

Metersky was skeptical that VAP is that much of a contributor to mortality, pointing to other studies that show a lower rate of VAP in pneumonia patients than was found in Singer’s study.

“Yes, some patients who are put on a ventilator will develop a fatal complication,” Metersky said. “Probably 1 in 100” patients put on a ventilator develop fatal VAP, he said, based on data from before the pandemic. Since about twice as many COVID-19 patients develop VAP compared with other pneumonia patients on ventilators, he said that would indicate that around 2% of people with COVID-19 who go on a ventilator die of VAP.

“But there are other complications,” Metersky said. These can include damage to the lungs from high oxygen and the air pressure from the ventilator or side effects from drugs used to sedate people on ventilators, for instance. “That’s why we don’t put a patient on a ventilator unless they absolutely need it,” he said.

Regardless, “it’s ridiculous to go from that study to say that the ventilators are killing all these people,” Metersky said, referring to the claim that nearly all COVID-19 deaths were caused by ventilators.

Early Ventilation Did Not Cause Mass Deaths

Other false claims, reviewed previously by others, state that overuse of ventilators played a major role in the first wave of COVID-19 deaths.

There were some suggestions very early in the pandemic that doctors should put COVID-19 patients on ventilators earlier than other pneumonia patients, Singer and Metersky both said, out of concern that respiratory failure might progress very quickly. 

This was soon followed by calls for caution in ventilating patients early, and these practices quickly stopped, Singer said. “The standard indications for initiation of mechanical ventilation are really the same as they always have been” for patients with pneumonia, he said, regardless of whether they have COVID-19.

Multiple facts about the early ventilation recommendations are unclear. First, there was no standard definition of what experts meant when recommending “early” ventilation. Decisions on when patients require mechanical ventilation are based on the best judgment of their doctors as they monitor multiple indicators. Doctors want to be sure the ventilator is truly necessary — that the patient is headed toward death from respiratory failure without it. But they also don’t want to wait until the patient has organ damage from lack of oxygen.

Second, it’s unclear how widespread early ventilation was. Singer mentioned that his own recent paper showed that Northwestern Medicine put patients with COVID-19 on ventilators after a similar amount of time in the ICU as other pneumonia patients. Others have pointed out that some doctors at the beginning of the pandemic took measures to avoid putting patients on ventilators due to shortages.

Finally, it’s uncertain what impact early ventilation had on patients. The available research, recently reviewed in a blog post by epidemiologist Gideon Meyerowitz-Katz, a Ph.D. candidate at the University of Wollongong in Australia, indicates that early versus later ventilation did not appreciably affect COVID-19 deaths. For instance, a review study that pooled and analyzed data from multiple studies found that going on a ventilator within a day of entering the ICU versus later had no impact on mortality.

It is possible that people occasionally were put on ventilators who could have avoided them, but this is difficult to quantify.

“There were probably a small number of patients who got put on a ventilator who ultimately might not have needed it,” Metersky said. “As we learned more about the disease, we learned to recognize that some patients may not need the ventilator. But it wasn’t this big conspiracy that we put everyone on the ventilator even though they could have gone home instead.”

Editor’s note: SciCheck’s articles providing accurate health information and correcting health misinformation are made possible by a grant from the Robert Wood Johnson Foundation. The foundation has no control over FactCheck.org’s editorial decisions, and the views expressed in our articles do not necessarily reflect the views of the foundation.

Sources

“Pulmonary Manifestations.” COVID-19 Real-Time Learning Network. Updated 22 Feb 2022.

Tobin, Martin and Manthous, Constantine. “Mechanical Ventilation.” American Journal of Respiratory and Critical Care Medicine. Published 15 Jul 2017. Updated April 2020.

Adl-Tabatabai, Sean. “Official Report: Ventilators Killed Nearly ALL COVID Patients.” The People’s Voice. 13 May 2023.

Jones, Brea. “Posts Fabricate Charge Against Bill Gates in Philippines.” FactCheck.org. 10 Mar 2023.

Spencer, Saranac Hale. “Hate Crimes Hotline Headline Is Wrong.” FactCheck.org. 30 Nov 2018.

Yandell, Kate. “Posts Share Fake Chelsea Clinton Quote About Global Childhood Vaccination Effort.” FactCheck.org. 10 May 2023.

Gao, Catherine A. et al. “Machine Learning Links Unresolving Secondary Pneumonia to Mortality in Patients with Severe Pneumonia, Including COVID-19.” The Journal of Clinical Investigation. 27 Apr 2023.

Massie, Thomas (@RepThomasMassie). “How many COVID patients died due to the use of ventilators? A recent examination of the data suggests quite a few. ‘The investigators found nearly half of patients with COVID-19 develop a secondary ventilator-associated bacterial pneumonia.’” Twitter. 15 May 2023.

Nolan, Margaret B. et al. “Mortality Rates by Age Group and Intubation Status in Hospitalized Adult Patients From 21 United States Hospital Systems During Three Surges of the COVID-19 Pandemic.” Chest. 29 Jan 2023.

“Frequently Asked Questions about Ventilator-Associated Pneumonia.” CDC website. Updated 9 May 2019.

Adele – Conspiracy Queen ???? (@truth.bomb.mom). “Such a bummer that this happened ????.” Instagram. 21 May 2023.

Fichera, Angelo. “Hospital Payments and the COVID-19 Death Count.” FactCheck.org. 21 Apr 2020.

Kertscher, Tom. “Fact-Check: Hospitals and COVID-19 Payments.” PolitiFact. 21 Apr 2020.

“Pneumonia – Causes and Risk Factors.” NIH website. Updated 24 March 2022.

“Pneumonia – What Is Pneumonia?” NIH website. Updated 24 Mar 2022.

Kohbodi, GoleNaz A. et al. “Ventilator-Associated Pneumonia.” Updated 10 Sep 2022.

Metersky, Mark L. et al. “Trend in Ventilator-Associated Pneumonia Rates Between 2005 and 2013.” JAMA. 13 Dec 2016.

Melsen, Wilhelmina G., et al. “Attributable Mortality of Ventilator-Associated Pneumonia: A Meta-Analysis of Individual Patient Data from Randomised Prevention Studies.” Lancet Infectious Diseases. 25 Apr 2013.

Metersky, Mark L. et al. “Temporal Trends in Postoperative and Ventilator-Associated Pneumonia in the United States.” Infection Control and Hospital Epidemiology. 3 Nov 2022.

Meyerowitz-Katz, Gideon. “Did Ventilators Kill People During COVID-19?” Medium. 25 May 2023.

Howard, Jonathan. “Intubations and Accusations: Doctors Were ‘Just Going Crazy, and Intubating People Who Did Not Have to Be Intubated.’” Science-Based Medicine. 19 Sep 2021.

Tobin, Martin J. et al. “Caution about Early Intubation and Mechanical Ventilation in COVID-19.” Annals of Intensive Care. 9 Jun 2020.

Anesi, George L. “COVID-19: Respiratory care of the nonintubated hypoxemic adult (supplemental oxygen, noninvasive ventilation, and intubation).” UpToDate. Updated 22 May 2023.

Marino, Ryan (@RyanMarino). “And -anecdotally- I was treating COVID patients in 2020. It was bleak and terrifying. They were incredibly sick and we actually did not have enough ventilators as we needed for this disease. I still remember the panicky feeling of using every possible attempt to avoid intubation.” Twitter. 15 May 2023.

Mansfield, Erin. “As the Coronavirus Curve Flattened, Even Hard-Hit New York Had Enough Ventilators.” USA Today. 28 Apr 2020.

Papoutsi, Eleni et al. “Effect of Timing of Intubation on Clinical Outcomes of Critically Ill Patients with COVID-19: A Systematic Review and Meta-Analysis of Non-Randomized Cohort Studies.” Critical Care. 25 Mar 2021.



Source link

SciCheck Digest

Ventilators can be lifesaving for critically ill COVID-19 patients. A social media claim that a new study shows ventilators killed “nearly all” COVID-19 patients is “quite wrong,” according to the study’s co-author. Ventilator-associated complications can contribute to deaths, but patients are typically put on ventilators when they would otherwise die.


Full Story

COVID-19 can cause lung damage and respiratory failure. In patients who are unable to breathe well enough to supply oxygen to their bodies, mechanical ventilators can be lifesaving and give them time to recover. Ventilators help people breathe by pushing air into their lungs via a tube inserted down their windpipe.

Yet, social media posts have shared an article from the People’s Voice with a false headline: “Official Report: Ventilators Killed Nearly ALL COVID Patients.” The People’s Voice, formerly News Punch, frequently publishes articles with false and inflammatory headlines.

The posts misrepresent the conclusions of a study published in April in the Journal of Clinical Investigation. The idea that ventilators — and not COVID-19 — killed nearly all COVID-19 patients is “quite wrong,” study co-author Dr. Benjamin Singer, a pulmonary and critical care physician at Northwestern Medicine, told us.

Rep. Thomas Massie, a Republican from Kentucky, also misrepresented the conclusions of the study, tweeting, “How many COVID patients died due to the use of ventilators? A recent examination of the data suggests quite a few.”

The idea that ventilators are dangerous, and not COVID-19, is a misinterpretation of his data, Singer said. “It’s not the ventilator that was the cause of death,” he said. “The ventilator was very much life support for these patients. It was ultimately COVID-19” that caused the deaths.

Singer’s study looked at 585 people put on ventilators due to respiratory failure between 2018 and 2022 at Northwestern Memorial Hospital. These people primarily had COVID-19 or some other infectious disease, such as another viral or bacterial illness.

Around half of these very sick patients who required mechanical ventilation — people who likely would have died without the intervention — went on to survive their illness. The survival rate was similar whether they had COVID-19 or another disease and was consistent with the survival rate for COVID-19 patients on ventilators found in another, larger study.

Singer’s study explored the degree to which a known ventilator-related complication called ventilator-associated pneumonia contributes to death, finding that the complication is more common in people with COVID-19 and, when unresolved, is linked to death. VAP is usually treated with antibiotics.

People with COVID-19 likely have an elevated risk of VAP because they stay on ventilators for longer-than-average periods. COVID-19 also affects the immune system and damages the surface of the lungs in unique ways, Singer said, which could potentially make the lungs more susceptible to secondary infections.

VAP contributes to death in some COVID-19 and other infectious disease patients, explained Dr. Mark Metersky, a pulmonary and critical care physician and professor at the University of Connecticut School of Medicine who was not involved in the study.

However, virtually all of these patients would have died if they had not been put on a ventilator, he said. “It’s not that the ventilator killed them, the ones who died. It’s that the ventilator failed to save them.”

A related claim in a popular post — that medical professionals put patients on ventilators due to financial incentives — is also unsupported by evidence, as we and other fact-checkers previously explained. It’s standard for hospitals to get more money for patients, such as those on ventilators, who require more care.

Study Explored Ventilator-Related Pneumonia

VAP typically occurs as a form of secondary pneumonia, which means it shows up in patients who already have another pneumonia diagnosis, such as pneumonia resulting from COVID-19, the flu or a bacterial infection.

People are diagnosed with pneumonia when their lungs become swollen with fluid from a respiratory infection. VAP typically arises from bacteria introduced to the lungs via the patient’s breathing tube.

Singer’s new paper finds that once very sick COVID-19 patients are on ventilators, they are at greater risk of VAP compared with other similarly ill pneumonia patients, he said.

Further, the paper found that “whether that ventilator-associated pneumonia was cured or not was a major determinant of whether patients went on to live or die in the ICU,” he said. However, just being diagnosed with VAP was not associated with a higher risk of death.

Based on these conclusions, the People’s Voice article makes a false claim, which was shared widely: “Nearly all COVID-19 patients who died in hospital during the early phase of the pandemic were killed as a direct result of being put on a ventilator, a disturbing new report has concluded.”

First, many hospitalized COVID-19 patients have died who never went on ventilators. And Singer’s study was not limited to “the early phase of the pandemic” but rather went through March 2022.

As we’ve said, this line of thinking is also misleading because it does not make it clear that the patients on ventilators would have typically died without them. It is also untrue that Singer’s study showed that ventilator-related complications killed “nearly all” ventilated patients who died.

The People’s Voice article explains its reasoning by saying that “most patients” put on ventilators because of COVID-19 developed VAP. “So while COVID-19 may have put these patients in the hospital, it was actually a secondary infection brought on by the use of a mechanical ventilator that caused their deaths,” the article says.

In reality, 57% of COVID-19 patients on ventilators in the study developed VAP and a quarter of other ventilated pneumonia patients did. Around half of all patients with VAP died, which was “not significantly different” from the death rate in patients on ventilators who didn’t have VAP, according to the study.

Singer and his colleagues did find that patients whose VAP was not successfully treated were more likely to die than patients whose VAP resolved, indicating a connection between VAP and poor outcomes. The study was not randomized, and the researchers write that they cannot definitively determine that unresolved VAP — and not some other factor associated with it — leads to poor outcomes.

Metersky was skeptical that VAP is that much of a contributor to mortality, pointing to other studies that show a lower rate of VAP in pneumonia patients than was found in Singer’s study.

“Yes, some patients who are put on a ventilator will develop a fatal complication,” Metersky said. “Probably 1 in 100” patients put on a ventilator develop fatal VAP, he said, based on data from before the pandemic. Since about twice as many COVID-19 patients develop VAP compared with other pneumonia patients on ventilators, he said that would indicate that around 2% of people with COVID-19 who go on a ventilator die of VAP.

“But there are other complications,” Metersky said. These can include damage to the lungs from high oxygen and the air pressure from the ventilator or side effects from drugs used to sedate people on ventilators, for instance. “That’s why we don’t put a patient on a ventilator unless they absolutely need it,” he said.

Regardless, “it’s ridiculous to go from that study to say that the ventilators are killing all these people,” Metersky said, referring to the claim that nearly all COVID-19 deaths were caused by ventilators.

Early Ventilation Did Not Cause Mass Deaths

Other false claims, reviewed previously by others, state that overuse of ventilators played a major role in the first wave of COVID-19 deaths.

There were some suggestions very early in the pandemic that doctors should put COVID-19 patients on ventilators earlier than other pneumonia patients, Singer and Metersky both said, out of concern that respiratory failure might progress very quickly. 

This was soon followed by calls for caution in ventilating patients early, and these practices quickly stopped, Singer said. “The standard indications for initiation of mechanical ventilation are really the same as they always have been” for patients with pneumonia, he said, regardless of whether they have COVID-19.

Multiple facts about the early ventilation recommendations are unclear. First, there was no standard definition of what experts meant when recommending “early” ventilation. Decisions on when patients require mechanical ventilation are based on the best judgment of their doctors as they monitor multiple indicators. Doctors want to be sure the ventilator is truly necessary — that the patient is headed toward death from respiratory failure without it. But they also don’t want to wait until the patient has organ damage from lack of oxygen.

Second, it’s unclear how widespread early ventilation was. Singer mentioned that his own recent paper showed that Northwestern Medicine put patients with COVID-19 on ventilators after a similar amount of time in the ICU as other pneumonia patients. Others have pointed out that some doctors at the beginning of the pandemic took measures to avoid putting patients on ventilators due to shortages.

Finally, it’s uncertain what impact early ventilation had on patients. The available research, recently reviewed in a blog post by epidemiologist Gideon Meyerowitz-Katz, a Ph.D. candidate at the University of Wollongong in Australia, indicates that early versus later ventilation did not appreciably affect COVID-19 deaths. For instance, a review study that pooled and analyzed data from multiple studies found that going on a ventilator within a day of entering the ICU versus later had no impact on mortality.

It is possible that people occasionally were put on ventilators who could have avoided them, but this is difficult to quantify.

“There were probably a small number of patients who got put on a ventilator who ultimately might not have needed it,” Metersky said. “As we learned more about the disease, we learned to recognize that some patients may not need the ventilator. But it wasn’t this big conspiracy that we put everyone on the ventilator even though they could have gone home instead.”

Editor’s note: SciCheck’s articles providing accurate health information and correcting health misinformation are made possible by a grant from the Robert Wood Johnson Foundation. The foundation has no control over FactCheck.org’s editorial decisions, and the views expressed in our articles do not necessarily reflect the views of the foundation.

Sources

Pulmonary Manifestations.” COVID-19 Real-Time Learning Network. Updated 22 Feb 2022.

Tobin, Martin and Manthous, Constantine. “Mechanical Ventilation.” American Journal of Respiratory and Critical Care Medicine. Published 15 Jul 2017. Updated April 2020.

Adl-Tabatabai, Sean. “Official Report: Ventilators Killed Nearly ALL COVID Patients.” The People’s Voice. 13 May 2023.

Jones, Brea. “Posts Fabricate Charge Against Bill Gates in Philippines.” FactCheck.org. 10 Mar 2023.

Spencer, Saranac Hale. “Hate Crimes Hotline Headline Is Wrong.” FactCheck.org. 30 Nov 2018.

Yandell, Kate. “Posts Share Fake Chelsea Clinton Quote About Global Childhood Vaccination Effort.” FactCheck.org. 10 May 2023.

Gao, Catherine A. et al. “Machine Learning Links Unresolving Secondary Pneumonia to Mortality in Patients with Severe Pneumonia, Including COVID-19.” The Journal of Clinical Investigation. 27 Apr 2023.

Massie, Thomas (@RepThomasMassie). “How many COVID patients died due to the use of ventilators? A recent examination of the data suggests quite a few. ‘The investigators found nearly half of patients with COVID-19 develop a secondary ventilator-associated bacterial pneumonia.’” Twitter. 15 May 2023.

Nolan, Margaret B. et al. “Mortality Rates by Age Group and Intubation Status in Hospitalized Adult Patients From 21 United States Hospital Systems During Three Surges of the COVID-19 Pandemic.” Chest. 29 Jan 2023.

Frequently Asked Questions about Ventilator-Associated Pneumonia.” CDC website. Updated 9 May 2019.

Adele – Conspiracy Queen ???? (@truth.bomb.mom). “Such a bummer that this happened ????.” Instagram. 21 May 2023.

Fichera, Angelo. “Hospital Payments and the COVID-19 Death Count.” FactCheck.org. 21 Apr 2020.

Kertscher, Tom. “Fact-Check: Hospitals and COVID-19 Payments.” PolitiFact. 21 Apr 2020.

Pneumonia – Causes and Risk Factors.” NIH website. Updated 24 March 2022.

Pneumonia – What Is Pneumonia?” NIH website. Updated 24 Mar 2022.

Kohbodi, GoleNaz A. et al. “Ventilator-Associated Pneumonia.” Updated 10 Sep 2022.

Metersky, Mark L. et al. “Trend in Ventilator-Associated Pneumonia Rates Between 2005 and 2013.” JAMA. 13 Dec 2016.

Melsen, Wilhelmina G., et al. “Attributable Mortality of Ventilator-Associated Pneumonia: A Meta-Analysis of Individual Patient Data from Randomised Prevention Studies.” Lancet Infectious Diseases. 25 Apr 2013.

Metersky, Mark L. et al. “Temporal Trends in Postoperative and Ventilator-Associated Pneumonia in the United States.” Infection Control and Hospital Epidemiology. 3 Nov 2022.

Meyerowitz-Katz, Gideon. “Did Ventilators Kill People During COVID-19?” Medium. 25 May 2023.

Howard, Jonathan. “Intubations and Accusations: Doctors Were ‘Just Going Crazy, and Intubating People Who Did Not Have to Be Intubated.'” Science-Based Medicine. 19 Sep 2021.

Tobin, Martin J. et al. “Caution about Early Intubation and Mechanical Ventilation in COVID-19.” Annals of Intensive Care. 9 Jun 2020.

Anesi, George L. “COVID-19: Respiratory care of the nonintubated hypoxemic adult (supplemental oxygen, noninvasive ventilation, and intubation).” UpToDate. Updated 22 May 2023.

Marino, Ryan (@RyanMarino). “And -anecdotally- I was treating COVID patients in 2020. It was bleak and terrifying. They were incredibly sick and we actually did not have enough ventilators as we needed for this disease. I still remember the panicky feeling of using every possible attempt to avoid intubation.” Twitter. 15 May 2023.

Mansfield, Erin. “As the Coronavirus Curve Flattened, Even Hard-Hit New York Had Enough Ventilators.” USA Today. 28 Apr 2020.

Papoutsi, Eleni et al. “Effect of Timing of Intubation on Clinical Outcomes of Critically Ill Patients with COVID-19: A Systematic Review and Meta-Analysis of Non-Randomized Cohort Studies.” Critical Care. 25 Mar 2021.



Source link

While COVID-19 and RSV cases have been declining in recent months, another, lesser-known respiratory virus surged this past spring.

A report released by the Centers for Disease Control and Prevention (CDC) on May 31 showed that positive PCR lab tests for human metapneumovirus (HMPV) in early March hit nearly 11 percent.

During the four years prior to the pandemic, positive results for HMPV testing peaked between 6.2 and 7.7 percent in March and April, according to the CDC. As the pandemic took off in the spring of 2020, HMPV decreased and remained low through May 2021.

“Human metapneumovirus has been around for awhile, but these numbers are higher than they've been in the last few years, so the virus is drawing attention,” says Panagis Galiatsatos, MD, a pulmonary and critical care physician with Johns Hopkins Medicine in Baltimore and a medical spokesperson for the American Lung Association.

Source link

Study associates sleep apnea in babies with increased risk of hypertension in adulthood
Exposure to intermittent hypoxia during the first 2 weeks of life (pCIH) elevates resting arterial blood pressure of rats at juvenile and adult ages. In the ventral lateral medulla, pCIH increases the expression of the hypoxia-inducible factor 1 alpha (HIF-1α) mRNA and the firing frequency of presympathetic neurons, leading to higher levels of vasoconstrictor sympathetic activity. Created with BioRender.com. Credit: SLEEP (2023). DOI: 10.1093/sleep/zsad055

Newborn babies who experience low levels of oxygen in their body tissues (hypoxia) due to sleep apnea, for example, tend to develop respiratory problems and hypertension (high blood pressure) in adulthood, and these problems may persist for the rest of their lives.

Research by scientists at São Paulo State University (UNESP) in Brazil shows for the first time that hypertension in these cases is caused by dysregulation of the autonomic nervous system, which controls involuntary physiological processes such as heart rate and breathing, as well as blood pressure.

An article on the study is published in the journal SLEEP.

The study involved an animal model and demonstrated that hypertension was associated with hyperactivity of the neurons in the sympathetic nervous system, the branch of the autonomic nervous system that is activated in response to stress.

"We discovered that rats that experienced episodes of intermittent hypoxia in the postnatal period displayed higher levels of neuronal activity in the lower part of the brainstem [i.e. the medulla oblongata] in youth and adulthood.

This may reflect adaptations of the brain to low levels of oxygen during a critical stage of development, including heightened activity of the sympathetic autonomic nervous system, probably due to increased expression of a protein called hypoxia-inducible factor 1 alpha [HIF-1α] in medulla neurons," said Daniel Zoccal, last author of the article and a professor at the Araraquara Dental School (FOAr-UNESP).

According to Zoccal, increased expression of HIF-1α by medulla neurons leads to several alterations in the "reading" of other genes that control cellular activity. As a result, the neurons that express more HIF-1α become more active, leading to a narrowing of the blood vessels and higher blood pressure. This phenomenon is epigenetic, insofar as it is due to biochemical alterations in cells caused by environmental stimuli that activate or silence genes without changing the genome.

Besides the first-ever demonstration of the mechanisms involved in the association between sporadically low levels of oxygen in the postnatal period and hypertension in youth and adulthood, important clinical developments could be based on the research.

"Although the prevalence of hypertension is high at about 30% of the world population, its origins are still poorly understood. All we know is that there's a risk associated with factors such as obesity, sedentary lifestyles, kidney problems and consumption of salt, for example. The results of our study will serve as a basis for the development of novel therapies," Zoccal told Agência FAPESP.

The discovery also highlights the importance of experiences during infancy to the development of diseases. "We must take greater care with babies' breathing to prevent the development of disease in adulthood," he stressed. Episodes of sleep apnea are fairly common in newborns and can be more frequent in premature infants, whose central nervous systems and respiratory systems are not fully mature, babies with enlarged adenoids or tonsils, obese infants, and babies with other anatomical abnormalities.

Describing the entire mechanism behind hypertension due to hypoxia in human infants up to about two years of age can also contribute to the development of treatments for the 20% or so of patients with hypertension who do not respond well to anti-hypertensive drugs, Zoccal said.

Previous research showed that electrical activity in the interface between sympathetic nerves and blood vessels is heightened in patients with high blood pressure, and especially those who do not respond to medicational treatment. "They have narrower blood vessels, which raises their blood pressure," he said.

Postnatal chronic intermittent hypoxia

In the study, postnatal chronic intermittent hypoxia was induced in rats for the first ten days after birth. The hypoxic episodes were brief, with oxygen falling from 21% to 6% for 30 seconds every 10 minutes while they were asleep. This resulted in six episodes of sleep apnea per hour, equivalent to a case of moderate sleep apnea.

"In the clinic, there are cases of severe apnea where the patient experiences 30 or even 60 episodes per hour," Zoccal said.

After two weeks, the researchers stopped inducing hypoxia, and the animals were able to breathe normally. When the rats were 40 days and 90 days old—comparable to between 13 and 16 years old and between 40 and 50 years old in humans—the researchers measured physiological parameters such as blood pressure and heart rate.

Rats of both ages subjected to postnatal intermittent hypoxia displayed consistently higher blood pressure—between 10 and 20 millimeters of mercury (mmHg) above the control group. According to the results, blood pressure in young rats averaged 84±7 mmHg for the control group and 95±5 mmHg for the hypoxia group. For adult rats, the averages were 103±10 mmHg and 121±9 mmHg respectively. It should be pointed out that blood pressure levels are similar in rats and humans.

"In the study, we didn't analyze when animals became hypertense but confirmed that young rats already displayed alterations relating to blood pressure and were hypertense in adulthood," Zoccal said.

After concluding that intermittent hypoxia raised blood pressure, the researchers set out to investigate the sympathetic nervous system's contribution to this process.

A word of explanation is in place here. As noted earlier, the sympathetic nervous system is one branch of the autonomic nervous system. The other is the parasympathetic nervous system.

The sympathetic nervous system helps the body activate its "fight or flight" response to danger or a threat. Energy expenditure increases as it raises the heart rate and blood pressure, releases adrenalin, contracts and relaxes muscles, dilates the bronchi and pupils, accelerates respiration, and activates the sweat glands. The parasympathetic nervous system normalizes the internal organs once the threat has passed.

When they placed electrodes in contact with sympathetic nerves in young rats, the researchers observed more electrical impulses in the animals subjected to intermittent hypoxia than the control group. In adult rats, they used a pharmacological method that led to the same result as the tests involving young rats. "We administered a drug that inhibits the actions of the sympathetic nervous system, and depending on the drop in blood pressure, it was possible to infer that sympathetic activity was augmented," Zoccal said.

The researchers also analyzed neuronal activity in the medulla oblongata, the bottom of the brainstem, responsible for regulating autonomic functions such as sneezing, breathing and heart rate, as well as sympathetic vasomotor tone and blood pressure.

"Our analysis focused on the ventral surface of the medulla, a key region for sympathetic activity to keep blood pressure at normal levels [about 12/8 mmHg in humans]. We found a higher firing rate for neurons in this region among the animals that had experienced postnatal intermittent hypoxia, pointing to dysfunction in this portion of the medulla due to exposure to hypoxia, which keeps sympathetic activity higher and raises blood pressure," Zoccal said.

They also found that neurons in the sympathetic nervous system expressed more HIF-1α. "This discovery enabled us to associate the entire process with a possible epigenetic cause," he said.

Zoccal recalled that the 2019 Nobel Prize in Physiology or Medicine was awarded to three scientists for their discoveries of how cells sense and adapt to oxygen availability, and that studies of HIF-1α were a significant part of their work. They discovered that levels of the protein increase when oxygen is low, inducing adaptations that assure the survival of cells and the organism during hypoxic conditions. Levels of HIF-1α decline when the supply of oxygen is normal.

The study focused on the effect of postnatal intermittent hypoxia on blood pressure due to sympathetic nervous system dysfunction, but alterations in this system are known to bring about other modifications, since sympathetic activity controls many functions in the organism, including body temperature and hence metabolism.

"In another study we published, using the same experimental model, the body weight of the animals that experienced hypoxia was lower than that of the control group, possibly owing to increased sympathetic activity. We also noted respiratory irregularities, with an abnormal pattern of acceleration and deceleration of resting pulmonary ventilation. In sum, these animals not only have high blood pressure but may also suffer from respiratory problems and probably from metabolic alterations as well," Zoccal said.

More information:
Marlusa Karlen-Amarante et al, Sympathetic dysregulation induced by postnatal intermittent hypoxia, SLEEP (2023). DOI: 10.1093/sleep/zsad055

Journal information:
Sleep


Citation:
Study associates sleep apnea in babies with increased risk of hypertension in adulthood (2023, May 31)
retrieved 1 June 2023
from medicalxpress.com/news/2023-05-associates-apnea-babies-hypertension-adulthood.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.



Source link

By MIKE STOBBE AP Medical Writer

NEW YORK (AP) — Racial bias built into a common medical test for lung function is likely leading to fewer Black patients getting care for breathing problems, a study published Thursday suggests.

As many as 40% more Black male patients in the study might have been diagnosed with breathing problems if current diagnosis-assisting computer software was changed, the study said.

Doctors have long discussed the potential problems caused by race-based assumptions that are built into diagnostic software. This study, published in JAMA Network Open, offers one of the first real-world examples of how the the issue may affect diagnosis and care for lung patients, said Dr. Darshali Vyas, a pulmonary care doctor at Massachusetts General Hospital.

The results are "exciting" to see published but it's also "what we'd expect" from setting aside race-based calculations, said Vyas, who was an author of an influential 2020 New England Journal of Medicine article that catalogued examples of how race-based assumptions are used in making doctors' decisions about patient care.

For centuries, some doctors and others have held beliefs that there are natural racial differences in health, including one that Black people's lungs were innately worse than those of white people. That assumption ended up in modern guidelines and algorithms for assessing risk and deciding on further care. Test results were adjusted to account for — or "correct" for — a patient's race or ethnicity.

One example beyond lung function is a heart failure risk-scoring system that categorizes Black patients as being at lower risk and less likely to need referral for special cardiac care. Another is an equation used in determining kidney function that creates estimates of higher kidney function in Black patients.

The new study focused on a test to determine how much and how quickly a person can inhale and exhale. It's often done using a spirometer — a device with a mouthpiece connected to a small machine.

After the test, doctors get a report that has been run through computer software and scores the patient's ability breathe. It helps indicate whether a patient has restrictions and needs further testing or care for things like asthma, chronic obstructive pulmonary disorder or lung scarring due to air pollutant exposure.

Algorithms that adjust for race raise the threshold for diagnosing a problem in Black patients and may make them less likely to get started on certain medications or to be referred for medical procedures or even lung transplants, Vyas said.

While physicians also look at symptoms, lab work, X-rays and family histories of breathing problems, the pulmonary function testing can be an important part of diagnoses, "especially when patients are borderline," said Dr. Albert Rizzo, the chief medical officer at the American Lung Association.

The new study looked at more than 2,700 Black men and 5,700 white men tested by University of Pennsylvania Health System doctors between 2010 and 2020. The researchers looked at spirometry and lung volume measurements and assessed how many were deemed to have breathing impairments under the race-based algorithm as compared to under a new algorithm.

Researchers concluded there would be nearly 400 additional cases of lung obstruction or impairment in Black men with the new algorithm.

Earlier this year, the American Thoracic Society, which represents lung-care doctors, issued a statement recommending replacement of race-focused adjustments. But the organization also put a call out for more research, including into the best way to modify software and whether making a change might inadvertently lead to overdiagnosis of lung problems in some patients.

Vyas noted some other algorithms have already been changed to drop race-based assumptions, including one for pregnant women that predicts risks of vaginal delivery if the mom previously had a cesarean section.

Changing the lung-testing algorithm may take longer, Vyas said, especially if different hospitals use different versions of race-adjusting procedures and software.

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group. The AP is solely responsible for all content.

Copyright 2023 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Source link

During the height of the coronavirus pandemic, when masking was required across much of the country and people were staying home, cases of illnesses like the flu and RSV decreased.

But viruses are spreading once again now that many people are returning to their pre-pandemic habits. RSV cases surged this past fall and cases of norovirus (often referred to as the stomach bug) increased this past winter. And there’s another virus that infected more people than usual this year ― which may explain why you were sick but tested negative for COVID or other better-known viruses.

According to the Centers for Disease Control and Prevention, human metapneumovirus cases (or HMPV) increased to higher-than-normal levels this past winter, with the peak happening in mid-March.

The illness “is related genetically to RSV, which people are probably more familiar with ... it’s what we call an RNA virus and that causes mainly respiratory disease similar to other respiratory viruses,” said Dr. Cesar A. Arias, the chief of the infectious diseases division at Houston Methodist Hospital and co-director of the Center for Infectious Diseases Research at Houston Methodist Research Institute in Texas.

For many people, HMPV presents as a common cold.

“The thing that is making people concerned about this right now is the positivity rate that the CDC reported on their surveillance of the past few months shows that it hit [very high] levels that I don’t believe it’s hit, at least in the recent past,” said Dr. Scott Roberts, an infectious diseases doctor at Yale Medicine and assistant professor of medicine at Yale School of Medicine in Connecticut.

In pre-COVID days, a 7% positivity rate for HMPV was considered normal. In mid-March of this year, the positivity rate was 11%, Roberts said. “Which suggests that, certainly, we had a much worse year for human metapneumovirus than previously,” he explained.

So, how worried do you need to be about this virus — and what are the signs that you may be infected? Here’s what to know:

In most people, HMPV symptoms align with common seasonal cold viruses.

Nasal congestion, sore throat, cough, fever and sometimes wheezing are among the reported symptoms, with laryngitis and bronchitis occurring in rare cases, according to Arias.

Arias noted that symptoms differ in children and adults, and children, particularly those under 1, are more likely to experience wheezing. As for adults, Roberts said, “I think actually cough was in 100% of adults who had been diagnosed with this, so it’s quite common.”

It’s riskiest for young children, elderly people and those with certain underlying conditions.

“I sort of liken this akin to RSV, where most people have nothing to worry about, it’s another cold virus,” said Roberts.

For most people, the symptoms will pass in a few days. But for some people, as with RSV and COVID-19, complications can occur.

There’s a subset of the population that [doesn’t] do as well with this and it includes the extremes of age and the immunocompromised — so the very young, the very old and then those with weakened immune systems,” Roberts said.

Arias said people with asthma, chronic obstructive pulmonary disease (also known as COPD), people who have cancer and those who are on immunosuppressive medication are all examples of people who are at higher risk.

“The worrisome symptom to me with any respiratory virus infection is when it sort of changes from an upper respiratory infection to a lower respiratory infection,” Roberts said. “People start to get short of breath and in severe cases need to come in to the hospital to get oxygen therapy.”

Roberts said this is pretty rare overall, and it usually happens in the groups mentioned above. That’s why it’s important to be cautious around people who may be at risk.

Symptoms are slightly different in children and adults, but, overall, this is a "common cold" virus.

Halfpoint Images via Getty Images

Symptoms are slightly different in children and adults, but, overall, this is a "common cold" virus.

HMPV spreads through coughing, sneezing and touch.

Similar to COVID-19 and other respiratory illnesses, it spreads through secretions from coughing and sneezing, Roberts said.

It also spreads through “touching, like shaking hands, touching contaminated objects without wiping them and then touching your nose or your mouth, which distinguishes this somewhat from COVID, which really doesn’t spread through touch,” he noted.

This makes hand-washing important to reduce your risk of getting sick. Additionally, you should avoid close contact with people who are sick and wear a mask if you choose, Roberts said.

It’s most prevalent in the winter and spring.

“This is usually a winter-spring virus instead of a fall virus. But otherwise, it’s really similar to the viruses we see,” Roberts said.

But that doesn’t mean the chances of catching it this summer are zero.

“I think, in general, the CDC data ... reported the surge is already over pretty much,” Roberts said. “But I think it’s [necessary] to know that we’re continuing to see changes in ... the epidemiological behavior of a number of viruses that previously we did not have too many concerns about.”

It’s believed that virus behavior is changing because of the COVID-19 pandemic.

There are several thoughts behind COVID’s impact on other viruses, but Roberts said the full extent is not known. Part of it, he said, reflects the “years of lost immunity through COVID where all of our public health interventions did work,” when people — specifically children — were not exposed to viruses for years. So, kids often get sick en masse now.

Mask-wearing and isolation rules reduced the spread of these common viruses, Arias agreed. “I think like we saw with RSV and other viruses, [there’s] maybe a little bit of a rebound of these viruses now, circulating much more because we have sort of moved forward on the isolation and these precautions,” he added.

Arias said we will continue to see this virus, and Roberts noted that it’s important to keep an eye on it during future seasons.

We’re going into the summer, and almost all respiratory viruses go down in the summer for a variety of reasons. My sense is this is only going to continue to get better until the fall or winter,” Roberts said.



Source link

Last night, Pfizer Inc. announced the US Food and Drug Administration (FDA) approved their respiratory syncytial virus (RSV) vaccine, Abrysvo, for older adults. This approval allows the use of Abrysvo in individuals aged 60 years and older to prevent lower respiratory tract disease caused by RSV.

Abrysvo, Pfizer's bivalent RSV prefusion F (RSVpreF) vaccine, is composed of 2 preF proteins specifically chosen to optimize protection against RSV A and B strains. With this approval, the FDA indicates all available trial data has proven Abrysvo to be safe and effective.

“A vaccine to help prevent RSV had been an elusive public health goal for more than half a century," stated Annaliesa Anderson, PhD, senior vice president and chief scientific officer of vaccine research and development at Pfizer. “Abrysvo will address a need to help protect older adults against the potentially serious consequences of RSV disease. We are extremely grateful to the clinical trial participants, study investigator teams and our dedicated Pfizer colleagues for their roles in making this vaccine available.”

In the more than 50 years of working to develop an RSV vaccine, Abrysvo is the world’s second-ever to be granted approval. Last month, GSK’s Arexvy (RSVPreF3 +AS01E) was approved to prevent lower respiratory tract disease (LRTD) caused by RSV in adults 60 years and older.

The FDA's decision to approve Abrysvo as well was based on data obtained from the pivotal Phase 3 clinical trial (NCT05035212) known as RENOIR (RSV vaccine Efficacy study iNOlder adults Immunized against RSV disease). RENOIR is a global, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, immunogenicity, and safety of a single dose of the vaccine in adults aged 60 and older.

Approximately 37000 participants were enrolled in RENOIR, with half receiving RSVpreF 120 μg and the other half receiving placebo in a 1:1 ratio. RENOIR is an ongoing study, with efficacy data being collected during the second RSV season.

Edward E. Walsh, MD, Professor of Medicine at the University of Rochester Medical Center and principal investigator of the RENOIR trial, commented, "This past RSV season demonstrated the serious consequences and potential health risks this virus poses for older adults. Today’s FDA approval of Abrysvo recognizes significant scientific progress, and importantly helps provide older adults potential protection against RSV and an opportunity to improve community health by helping prevent the disease.”

RSV is a contagious virus that commonly causes respiratory illnesses worldwide. It primarily affects the lungs and breathing passages, often leading to severe illness or even death. In the US, RSV poses a considerable burden on older adults, with disease severity increasing with age and comorbidities such as chronic obstructive pulmonary disease, asthma, and congestive heart failure.

In most healthy individuals, RSV manifests with mild, cold-like symptoms. Most people recover within 2 weeks, often without knowing they had contracted RSV. Infants and young children, however, are also susceptible to the worst of RSV infection. Thus, Pfizer is also seeking approval to administer RSVpreF to pregnant persons, with the goal of preventing medically attended lower respiratory tract disease (MA-LRTD) and severe MA-LRTD caused by RSV in infants from birth to 6 months of age.

The maternal vaccine was recently recommended for approval by the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC), and a decision is expected by August 21, 2023.

Regarding the use of RSV vaccines in older adults, the US Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) is scheduled to meet on June 21, 2023, to discuss recommendations. Pending the outcome of this meeting, Pfizer expects Abrysvo to be available in the third quarter of 2023, just ahead of the anticipated RSV season this fall.

In addition to this recent approval, Pfizer reported positive top-line results earlier this month from a Phase 3 study that evaluated the safety and immunogenicity of Abrysvo coadministered with seasonal inactivated influenza vaccine (SIIV) in adults aged 65 and older.

Furthermore, Pfizer announced its plans to conduct multiple clinical trials evaluating RSVpreF in healthy children aged 2-5 years, children aged 5-18 years with comorbidities, adults aged 18-60 years with comorbidities, and adults aged 18 years and older who are immunocompromised and at high risk for adverse RSV outcomes.

Contagion is actively following all developments in the RSV space. Return soon for updates, or click here to browse our past breaking news coverage and interviews with lead researchers.

Source link

Patients with chronic obstructive pulmonary disease (COPD) using triple therapy (TT; fluticasone furoate/umeclidinium/vilanterol) who are not maintenance-naïve have a 7% lower risk of exacerbations but have higher treatment costs than patients using dual therapy (tiotropium/olodaterol), according to study findings published in the Journal of Managed Care + Specialty Pharmacy.

Dual long-acting muscarinic antagonists (LAMAs)/long-acting β2-agonists (LABAs) are the preferred maintenance therapy over LAMA or LABA monotherapy for patients with chronic obstructive pulmonary disease (COPD), according to the American Thoracic Society 2020 Clinical Practice Guidelines. Patients with COPD with exercise intolerance or dyspnea may be escalated to TT (LAMA/LABA/inhaled corticosteroid [ICS]) or TT may be used as initial therapy for certain patients with high exacerbation risk.

Investigators sought to compare disease-related and all-cause health care resource utilization (HCRU) and costs, pneumonia events, and COPD exacerbations in patients with COPD initiating fixed-dose combinations of either LAMA/LABA (tiotropium/olodaterol [TIO+OLO]) or TT (fluticasone furoate/umeclidinium/vilanterol [FF+UMEC+VI]). The researchers also compared outcomes between the overall study population vs the maintenance-naïve population (ie, participants with no previous inhaled corticosteroids, LABA, or LAMA maintenance therapy in the prior 12 months).

This retrospective observational study used claims data from the Optum Research Database (including patients with commercial insurance and Medicare Advantage with Prescription Drug coverage) from June 2015 through November 2019 for patients at least 40 years of age with COPD who initiated TIO+OLO or FF+UMEC+VI. Cohorts of TIO+OLO and FF+UMEC+VI in the overall population (n=5658) and the maintenance-naïve population (n=3025) were propensity-score matched 1:1 on health care costs, health care utilization, COPD medications, comorbidities, and demographics. Clinical and economic outcomes up to 1 year in TIO+OLO vs FF+UMEC+VI post-matched cohorts were compared using multivariable regression.

A lower risk of exacerbation was observed with FF+UMEC+VI vs TIO+OLO in the overall population but not among the maintenance-naive population.

With respect to clinical outcomes in the overall study population, the investigators found no significant differences between the TIO+OLO vs FF+UMEC+VI cohorts in time to first COPD exacerbation (49.7% vs 50.8% at 1 year; P =.301) or time to first COPD severe exacerbation (18.7% vs 18.2% at 1 year; P =.459). Time to first pneumonia diagnosis was comparable across groups at 1 year, with 16.5% of patients in the dual therapy cohort vs 19.5% in the TT cohort diagnosed with pneumonia. 

In the maintenance-naïve population, investigators found there was no difference among dual and triple therapy cohorts in the adjusted risk of any exacerbation (adjusted hazard ratio [aHR], 0.99; 95% CI, 0.88-1.10). The researchers found no statistical difference for pneumonia risk between cohorts in the maintenance-naïve population (aHR, 1.13; 95% CI, 0.95-1.36) or in the overall population (aHR, 1.12; 95% CI, 0.98-1.27).

With respect to cost outcomes, investigators found that in the overall population, COPD- and/or pneumonia-related adjusted total annualized costs were significantly greater for TT ($17,633; 95% CI, 16,661-18,604) vs dual therapy ($14,558; 95% CI, 13,709-15,407; P <.001) (2020 US dollars), with patients using triple therapy paying $3075 (21.1%) more per year. Likewise, in the maintenance-naïve population, the adjusted total annualized cost of triple therapy was significantly greater than that of dual therapy (TT: $19,032; 95% CI, 17,466-20,598; vs dual therapy: $15,004; 95% CI, 13,786-16,223; P <.001; difference, $4028 [26.8%]).

Investigators noted significantly higher pharmacy costs with TT vs dual therapy, both in the overall population (TT: $6567; 95% CI, 6503-6632; vs dual therapy: $4729; 95% CI, 4676-4783; difference, $1838 [38.9%]), and in the maintenance-naïve population (TT: $6642; 95% CI, 6560-6724; vs dual therapy: $4750; 95% CI, 4676-4825; difference, $1892 [39.8%]) (all P <.001).

Notably, among the maintenance-naïve population, the FF+UMEC+VI cohort vs the TIO+OLO cohort had more annualized inpatient visits (0.5 vs 0.4; P =.029) and other medical visits (4.2 vs 3.7; P =.021).

Study limitations include selection bias and the relatively short exposure to study drugs.

“A lower risk of exacerbation was observed with FF+UMEC+VI vs TIO+OLO in the overall population but not among the maintenance-naive population,” investigators concluded. The researchers said their results indicated that real-world economic outcomes can be improved in the maintenance-naïve population with COPD by initiating dual LAMA/LABA therapy per practice guidelines.

Disclosure: This research was supported by Boehringer Ingelheim Pharmaceuticals, Inc. Some study authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of authors’ disclosures.

Source link

Pfizer received approval from the FDA for ABRYSVO (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older. ABRYSVO is unadjuvanted and composed of two preF proteins selected to optimize protection against RSV A and B strains and was observed to be safe and effective.
 
The decision is based on data from the Phase 3 clinical trial RENOIR, a global, randomized, double-blind, placebo-controlled study designed to assess the efficacy, immunogenicity, and safety of a single dose of the vaccine in adults 60 years of age and older. RENOIR has enrolled approximately 37,000 participants, randomized to receive RSVpreF 120 μg or placebo in a 1:1 ratio. RENOIR is ongoing, with efficacy data being collected in the second RSV season in the study.
 
Trial results published in April showed 67% efficacy in preventing infections with at least two symptoms. Protection was even greater against more severe disease, defined as three or more symptoms of RSV-related illness.
 
RSV is a contagious virus and a common cause of respiratory illness worldwide. The virus can affect the lungs and breathing passages of an infected individual, potentially causing severe illness or death. The severity of RSV disease can increase with age and comorbidities, such as chronic obstructive pulmonary disease, asthma, and congestive heart failure.
 
The U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) will meet on June 21, 2023, to discuss recommendations for the appropriate use of RSV vaccines in older adults. Pending the outcome of this meeting, Pfizer anticipates supply availability in Q3 2023 ahead of the anticipated RSV season this fall.
 
Pfizer reported positive results from the Phase 3 study evaluating the safety and immunogenicity of ABRYSVO co-administered with seasonal inactivated influenza vaccine (SIIV) in adults 65 years and older. Pfizer is initiating multiple clinical trials evaluating RSVpreF in healthy children ages 2-5; children ages 5-18 with underlying medical conditions; adults ages 18-60 at high-risk due to underlying medical conditions; and adults ages 18 and older who are immunocompromised and at high-risk for RSV.

Source link

By Cara Murez HealthDay Reporter

(HealthDay)

This significant smoke plume is likely to cause elevated levels of fine particulate matter, the American Lung Association warned in its alert. Particulate matter contains microscopic solids or liquid droplets that are so small that they can be inhaled and cause serious health problems, according to the U.S. Environmental Protection Agency.

The lung association also offered tips for everyone — but especially children, older adults and people with lung diseases like asthma and chronic obstructive pulmonary disease (COPD) — to stay well despite the poor air quality.

  • Start by staying indoors. If you live close to these areas where there is fire and a lot of smoke, stay inside to avoid breathing smoke, ashes and other pollution in the area.
  • Keep doors, windows and fireplace dampers shut, preferably with clean air circulating through air conditioners on the recirculation setting.
  • Watch your symptoms. With higher smoke levels, breathing can be more difficult. Call your doctor if you experience these symptoms.
  • Protect your children and teens, who are more susceptible to smoke. They breathe in more air — and more pollution — into their developing lungs for their size than adults do.
  • Ask for help. The American Lung Association’s Lung HelpLine at 1-800-LUNGUSA is staffed by nurses and respiratory therapists. They will answer your questions about the lungs, lung disease and lung health for free.

SOURCE: American Lung Association, news release, May 31, 2023

Copyright © 2023 HealthDay. All rights reserved.

Source link

ReportLinker

ReportLinker

Major players in the oxygen therapy market are Smiths Medical Inc., Hersill SL, Fisher & Paykel Healthcare Corporation Limited, Invacare Corporation, Teleflex Incorporated, Koninklijke Philips N.V., Drive Devilbiss International, Allied Healthcare Products Inc.

New York, June 01, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Oxygen Therapy Global Market Report 2023" - www.reportlinker.com/p06464234/?utm_source=GNW
, Becton, Dickinson and Company, General Electric Company, Getinge Group, Essex Industries Inc., Chart Industries Inc., Drägerwerk AG & Co. KGaA, GCE Group, Thermo Fisher Scientific Inc., OxyBand Technologies Inc., and Nidek Medical Products Inc.

The global oxygen therapy market is expected to grow from $23.70 billion in 2022 to $25.89 billion in 2023 at a compound annual growth rate (CAGR) of 9.3%.The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The oxygen therapy market is expected to reach $36.53 billion in 2027 at a CAGR of 9.0%.

The oxygen therapy market consists of sales of pulse oximeters, oxygen flow meters, portable oxygen supply devices, nasal cannulas, simple masks, non-rebreather masks, continuous positive airway pressure, BiPAP, bag valve mask (ambu bag), endotracheal intubation, and mechanical ventilator.Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers.

The value of goods in this market includes related services sold by the creators of the goods.

Oxygen therapy refers to using additional oxygen as part of sickness management in people suffering from respiratory problems who can’t naturally breathe in sufficient oxygen due to various diseases and ailments. Oxygen therapy provides persons with lung disorders or breathing difficulties with the oxygen their bodies require to operate.

North America was the largest region in the oxygen therapy market in 2022. The regions covered in oxygen therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main types of oxygen therapy products are oxygen delivery devices and oxygen source equipment.Oxygen delivery devices refer to secondary oxygen-providing equipment for people who cannot maintain a safe level of oxygen saturation and are used in oxygen therapy are controlling and monitor respiratory failure devices including nasal or transtracheal catheters, and nasal cannula.

The various types of portability include stationary devices and portable devices that are used in various applications such as pneumonia, chronic obstructive pulmonary disease, asthma, obstructive sleep apnea, respiratory distress syndrome, cystic fibrosis, and others. These are used in hospitals, clinics, home care, and post-acute care settings.

The rising prevalence of respiratory disorders is expected to propel the growth of the oxygen therapy market going forward.A respiratory disorder is a condition that impacts the respiratory system’s lungs and other organs, often known as lung diseases which include tuberculosis, lung cancer, mesothelioma, cystic fibrosis, and asthma.

Oxygen therapy is used in the treatment of people suffering from respiratory disorders condition by providing an additional supply of oxygen that relieves shortness of breath.For instance, in February 2023, according to the report published by American Lung Association, a US-based voluntary lung health and preventing lung disease, a chronic lung illness, such as asthma or COPD, which also includes emphysema and chronic bronchitis, affects more than 34 million Americans.

Additionally, more than 25 million Americans, including more than 4 million children, have breathing difficulties due to asthma. Therefore, the rise in the prevalence of respiratory disorders is driving the growth of the oxygen therapy market.

Technological advancements are a key trend gaining popularity in the oxygen therapy market.Companies operating in the oxygen therapy market are adopting new technologies to sustain their position in their market.

For instance, in July 2022, Omron Healthcare, a Japanese-based electrical equipment manufacturer company, launched a portable oxygen concentrator to assist home care providers in addressing the therapeutic and lifestyle needs of COPD and respiratory patients.This portable oxygen concentrator includes PSA (Pressure Swing Adsorption) technology that provides a continuous supply of oxygen (5L per minute).

Additionally, it employs medical molecular sieves to assure the efficiency and purity of the oxygen while maintaining the device’s mobility, making it easier to transport.

In January 2023, CAIRE Inc, a US-based medical equipment manufacturing company acquired MGC Diagnostics for an undisclosed amount.With this acquisition, CAIRE Inc aims to strengthen its portfolio in diagnostic technologies and to serve patients with pulmonary disease.

MGC Diagnostics is a US-based company involved in the manufacturing and sales of oxygen therapy tools such as pulse oximeters.

The countries covered in the oxygen therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The oxygen therapy market research report is one of a series of new reports that provides oxygen therapy market statistics, including the oxygen therapy industry global market size, regional shares, competitors with an oxygen therapy market share, detailed oxygen therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the oxygen therapy industry. This oxygen therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Read the full report: www.reportlinker.com/p06464234/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001

Source link

New York, June 01, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Bronchitis Treatment Global Market Report 2023" - www.reportlinker.com/p06464208/?utm_source=GNW
, Sun Pharmaceutical Industries Ltd., Pfizer Inc., Cipla Inc., Merck and Co. Inc., Bayer AG, Johnson & Johnson Private Limited, Viatris Inc., and Lupin Ltd.

The global bronchitis treatment market is expected to grow from $4.96 billion in 2022 to $5.24 billion in 2023 at a compound annual growth rate (CAGR) of 5.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The bronchitis treatment market is expected to reach $6.60 billion in 2027 at a CAGR of 5.9%.

The bronchitis treatment market includes revenues earned by entities by providing vaccines surgery, and pulmonary rehabilitation.The market value includes the value of related goods sold by the service provider or included within the service offering.

Only goods and services traded between entities or sold to end consumers are included.

Bronchitis treatment refers to a treatment of a condition in which the bronchial tubes, which carry air to and from the lungs, become inflamed and produce an excessive amount of mucus. This treatment includes symptom-relieving medications such as bronchodilators, steroids, and antibiotics.

North America was the largest region in the bronchitis treatment market in 2022.The regions covered in bronchitis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the bronchitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The bronchitis treatment is used to treat acute bronchitis and chronic bronchitis by using several types of treatment, including drugs and oxygen therapy.Acute bronchitis is a contagious viral infection that causes bronchial tube inflammation.

These are sold through various distribution channels, such as online pharmaceutical stores, retail pharmacies, and hospital pharmacies.

The increasing incidence of respiratory diseases is expected to propel the growth of the bronchitis treatment market going forward.Respiratory diseases refer to diseases that affect the lungs and other parts of the respiratory system.

This disease can affect the upper or lower respiratory tract and can be caused by a variety of factors, including infections, allergens, irritants, and genetic predispositions.Bronchitis treatment for respiratory diseases can be used in a number of ways, depending on the root cause and severity of the condition.

Bronchitis treatment include antibiotics, anti-inflammatories, and bronchodilators to open airways of respiratory organs.For instance, in November 2021, according to the Bureau of Labor Statistics, a US-based intergovernmental organization, The number of respiratory disease cases reported by employers increased by around 4,000%, from 10,800 in 2019 to 428,700 in 2020, which contributed to the growth in illness cases.

The rate of respiratory illness grew from 1.1 cases per 10,000 full-time equivalent workers in 2019 to 44.0 cases in 2020.. Therefore, the increasing incidence of respiratory diseases is driving the growth of the bronchitis treatment market going forward.

Product innovations are a key trend gaining popularity in the bronchitis treatment market.Major companies operating in the bronchitis treatment market are adopting new technologies to sustain their position in the market.

For instance, in June 2021, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, launched the first generic version of PERFOROMIST®, a formoterol fumarate inhalation solution. This solution is intended to treat bronchoconstriction in individuals with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Adults with COPD can manage their symptoms using formoterol fumarate inhalation solution, a long-acting beta2-adrenergic agonist (LABA). Emphysema, chronic bronchitis, or both may be present in COPD, a chronic lung illness. Only a nebulizer can be used to use formoterol fumarate inhalation solution.

In January 2022, Covis Pharma Group, a Switzerland-based specialty pharmaceutical company, acquired the respiratory portfolio of two medicines from AstraZeneca for $270 million.This transaction includes the acquisition of Eklira® and Duaklir®, which enables Covis to provide a comprehensive spectrum of best-in-class treatments for allergic rhinitis, asthma, and COPD (chronic obstructive pulmonary disease) and highlights its capacity to collaborate with and be a preferred partner for major pharmaceutical firms.

AstraZeneca PLC is a UK-based pharmaceutical and biotechnology company and a co-developer of a vaccine against bronchiolitis.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The bronchitis treatment market research report is one of a series of new reports that provides bronchitis treatment market statistics, including bronchitis treatment industry global market size, regional shares, competitors with a bronchitis treatment market share, detailed bronchitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the bronchitis treatment industry. This bronchitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Read the full report: www.reportlinker.com/p06464208/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________


        

Source link

Coughing is one of the symptoms of a respiratory virus known as human metapneumovirus, or HMPV.

Coughing is one of the symptoms of a respiratory virus known as human metapneumovirus, or HMPV.

Coughing is one of the symptoms of a respiratory virus known as human metapneumovirus, or HMPV.

During the height of the coronavirus pandemic, when masking was required across much of the country and people were staying home, cases of illnesses like the flu and RSV decreased.

But viruses are spreading once again now that many people are returning to their pre-pandemic habits. RSV cases surged this past fall and cases of norovirus (often referred to as the stomach bug) increased this past winter. And there’s another virus that infected more people than usual this year ― which may explain why you were sick but tested negative for COVID or other better-known viruses.

According to the Centers for Disease Control and Prevention, human metapneumovirus cases (or HMPV) increased to higher-than-normal levels this past winter, with the peak happening in mid-March.

The illness “is related genetically to RSV, which people are probably more familiar with ...  it’s what we call an RNA virus and that causes mainly respiratory disease similar to other respiratory viruses,” said Dr. Cesar A. Arias, the chief of the infectious diseases division at Houston Methodist Hospital and co-director of the Center for Infectious Diseases Research at Houston Methodist Research Institute in Texas.

For many people, HMPV presents as a common cold.

“The thing that is making people concerned about this right now is the positivity rate that the CDC reported on their surveillance of the past few months shows that it hit [very high] levels that I don’t believe it’s hit, at least in the recent past,” said Dr. Scott Roberts, an infectious diseases doctor at Yale Medicine and assistant professor of medicine at Yale School of Medicine in Connecticut. 

In pre-COVID days, a 7% positivity rate for HMPV was considered normal. In mid-March of this year, the positivity rate was 11%, Roberts said. “Which suggests that, certainly, we had a much worse year for human metapneumovirus than previously,” he explained.

So, how worried do you need to be about this virus — and what are the signs that you may be infected? Here’s what to know:

In most people, HMPV symptoms align with common seasonal cold viruses.

Nasal congestion, sore throat, cough, fever and sometimes wheezing are among the reported symptoms, with laryngitis and bronchitis occurring in rare cases, according to Arias.

Arias noted that symptoms differ in children and adults, and children, particularly those under 1, are more likely to experience wheezing. As for adults, Roberts said, “I think actually cough was in 100% of adults who had been diagnosed with this, so it’s quite common.”

It’s riskiest for young children, elderly people and those with certain underlying conditions. 

“I sort of liken this akin to RSV, where most people have nothing to worry about, it’s another cold virus,” said Roberts. 

For most people, the symptoms will pass in a few days. But for some people, as with RSV and COVID-19, complications can occur.

There’s a subset of the population that [doesn’t] do as well with this and it includes the extremes of age and the immunocompromised — so the very young, the very old and then those with weakened immune systems,” Roberts said.

Arias said people with asthma, chronic obstructive pulmonary disease (also known as COPD), people who have cancer and those who are on immunosuppressive medication are all examples of people who are at higher risk.

“The worrisome symptom to me with any respiratory virus infection is when it sort of changes from an upper respiratory infection to a lower respiratory infection,” Roberts said. “People start to get short of breath and in severe cases need to come in to the hospital to get oxygen therapy.”

Roberts said this is pretty rare overall, and it usually happens in the groups mentioned above. That’s why it’s important to be cautious around people who may be at risk.

Symptoms are slightly different in children and adults, but, overall, this is a

Symptoms are slightly different in children and adults, but, overall, this is a

Symptoms are slightly different in children and adults, but, overall, this is a "common cold" virus.

HMPV spreads through coughing, sneezing and touch.

Similar to COVID-19 and other respiratory illnesses, it spreads through secretions from coughing and sneezing, Roberts said.

It also spreads through “touching, like shaking hands, touching contaminated objects without wiping them and then touching your nose or your mouth, which distinguishes this somewhat from COVID, which really doesn’t spread through touch,” he noted. 

This makes hand-washing important to reduce your risk of getting sick. Additionally, you should avoid close contact with people who are sick and wear a mask if you choose, Roberts said.

It’s most prevalent in the winter and spring.

“This is usually a winter-spring virus instead of a fall virus. But otherwise, it’s really similar to the viruses we see,” Roberts said.

But that doesn’t mean the chances of catching it this summer are zero.

“I think, in general, the CDC data ... reported the surge is already over pretty much,” Roberts said. “But I think it’s [necessary] to know that we’re continuing to see changes in ... the epidemiological behavior of a number of viruses that previously we did not have too many concerns about.”

It’s believed that virus behavior is changing because of the COVID-19 pandemic.

There are several thoughts behind COVID’s impact on other viruses, but Roberts said the full extent is not known. Part of it, he said, reflects the “years of lost immunity through COVID where all of our public health interventions did work,” when people — specifically children — were not exposed to viruses for years. So, kids often get sick en masse now.

Mask-wearing and isolation rules reduced the spread of these common viruses, Arias agreed. “I think like we saw with RSV and other viruses, [there’s] maybe a little bit of a rebound of these viruses now, circulating much more because we have sort of moved forward on the isolation and these precautions,” he added.

Arias said we will continue to see this virus, and Roberts noted that it’s important to keep an eye on it during future seasons.

We’re going into the summer, and almost all respiratory viruses go down in the summer for a variety of reasons. My sense is this is only going to continue to get better until the fall or winter,” Roberts said.

Related...

Source link

Simple yet effective, pursed lip breathing has a significant positive effect on general well-being. You can enjoy a variety of benefits for your physical and mental health by actively managing your breath using a certain technique.

It's simple to forget the basic but profound act of breathing in the flurry of daily life. However, you can avail a multitude of health benefits by harnessing the power of breath through practices like pursed lip breathing.


Pursed lip breathing technique

It improves respiratory function. (Image via Unsplash/Joey Nicotra)
It improves respiratory function. (Image via Unsplash/Joey Nicotra)

It's crucial to comprehend and practice the pursed lip breathing method to effectively utilize the power of breath. You can quickly implement this method into your daily activities.

To assist you in mastering the method, below is a step-by-step manual:

  • Look for a peaceful location where you can sit or lie down.
  • The body should be at ease when you inhale deeply through your nose and fill your lungs with air.
  • Puck your lips as if you were about to extinguish a candle.
  • Exhale gradually through pursed lips, letting the breath leave the body easily and gently.
  • Focus on keeping a steady and regulated flow of breath as you continue to exhale for longer than you inhale.
  • For several minutes, go through this cycle again to give yourself time to settle into a rhythm.

Purpose of pursed lip breathing

This breathing technique serves several important purposes that contribute to better health and well-being. Let's examine in more detail:

1) Enhancing respiratory function

It increases air exchange during each breath, which enhances respiratory function by increasing lung capacity and efficiency. This method aids in keeping the airways open, reducing build-up of stale air and improving oxygenation.

2) Promoting relaxation and stress reduction

Pursed breathing helps in relieving stress. (Image via Unsplash/ Eli Defaria)
Pursed breathing helps in relieving stress. (Image via Unsplash/ Eli Defaria)

It activates the parasympathetic nervous system, which causes a relaxation response. That promotes relaxation and reduces stress, which lessens tension and anxiety while fostering a calm and healthy state of mind.

3) Chronic obstructive pulmonary disease symptom management

People with COPD can benefit greatly from this breathing technique. Breathlessness, labored breathing and symptom management can all be helped by slowing the breath and lengthening exhalation.

4) Supporting exercise performance and endurance

People who are physically active, like athletes, can gain benefits from this breathing technique. Limiting fast breathing and assisting in maintaining adequate oxygen levels for longer endurance, regulates breathing during exercise.

5) Facilitating better sleep and managing sleep disorders

It can be a helpful strategy for people who struggle with sleep disorders like sleep apnea in terms of promoting better sleep and managing sleep disorders. It can lead to greater sleep quality by enhancing relaxation and respiratory function.


Benefits of pursed lip breathing

This breathing technique improves oxygenation. (Image via Unsplash/Lutchenca Medeiros)
This breathing technique improves oxygenation. (Image via Unsplash/Lutchenca Medeiros)

Pursed lip breathing has numerous benefits for both physical and mental well-being. Let's examine a few of them:

Increased oxygenation: This breathing technique increases the effectiveness of oxygen exchange in the lungs, resulting in greater oxygenation of body tissues and improved general vigor.

Nervous system calming: Pursued lip breathing, which controls breath, activates the vagus nerve, inducing relaxation response and lowering stress and anxiety level.

Alleviating breathlessness and shortness of breath: Pursed lip breathing reduces the sensation of air hunger and slows down breathing rate. That makes it easier to engage in physical activity and lessens the discomfort connected with breathlessness.


Pursed lip breathing is a straightforward technique that has several benefits, including calming thoughts and lengthening exhalations.

You can use as many repetitions as you'd like. The need to exhale more frequently could indicate a respiratory disorder. In this situation, speak with your doctor for the next course of action.




Source link


Eleanor Squires Senior adult nursing lecturer, School of Health and Social Work, University of Hertfordshire, Hatfield, England



Why you should read this article:

  • To enhance your knowledge of the adverse effects of climate change on people’s health

  • To understand the ways climate change can aggravate asthma, chronic obstructive pulmonary disease and cardiovascular disease

  • To increase your awareness of your role in informing patients of the health implications of climate change

Climate change is one of the most significant global challenges and is already having detrimental effects on people’s health. Pollution levels and ambient temperatures continue to increase, resulting in higher levels of humidity and pollen production. These environmental threats can affect many vulnerable patients, particularly those with respiratory and cardiovascular conditions, and nurses have a crucial role in raising awareness of the health implications of climate change. This article explores the pathophysiological effects of climate change on patients with asthma, chronic obstructive pulmonary disease and cardiovascular disease, and aims to enhance nurses’ understanding of the health challenges of climate change.

Nursing Standard.
doi: 10.7748/ns.2023.e12087

Peer review

This article has been subject to external double-blind peer review and checked for plagiarism using automated software

Correspondence

[email protected]

Conflict of interest

None declared

Squires E (2023) Effects of climate change on patients with respiratory and cardiovascular conditions. Nursing Standard. doi: 10.7748/ns.2023.e12087

Published online: 01 June 2023

Want to read more?

Already subscribed? Log in

OR

Unlock full access to RCNi Plus today

Save over 50% on your first 3 months

Your subscription package includes:

  • Unlimited online access to all 10 RCNi Journals and their archives
  • Customisable dashboard featuring 200+ topics
  • RCNi Learning featuring 180+ RCN accredited learning modules
  • RCNi Portfolio to build evidence for revalidation
  • Personalised newsletters tailored to your interests

Subscribe

RCN student member? Try Nursing Standard Student

Alternatively, you can purchase access to this article for the next seven days. Buy now

Or

Source link